A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: SHR-A1811 for injection ; capecitabine
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.